Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="282882"/>
  <meta>
    <versionId value="4"/>
    <lastUpdated value="2024-10-15T18:33:30.190Z"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 282882</b></p><a name="282882"> </a><a name="hc282882"> </a><a name="282882-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 4; Last updated: 2024-10-15 18:33:30+0000</p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882.)</p><p><b>url</b>: <a href="https://fevir.net/resources/Group/282882">https://fevir.net/resources/Group/282882</a></p><p><b>identifier</b>: FEvIR Object Identifier/282882</p><p><b>title</b>: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Laboratory test</span></p><p><b>value</b>: <span title="Codes:{http://loinc.org 1558-6}">Fasting plasma glucose</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Unit of measure</span></p><p><b>value</b>: <span title="Codes:">mg/dL</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Method</span></p><p><b>value</b>: <span title="Codes:">Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis.   Plasma Fasting Glucose Laboratory Procedure Manual (August 2020)   https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf</span></p><p><b>exclude</b>: false</p></blockquote></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882."/>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/282882"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="282882"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title value="NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Laboratory test"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://loinc.org"/>
        <code value="1558-6"/>
        <display value="Fasting glucose [Mass/volume] in Serum or Plasma"/>
      </coding>
      <text value="Fasting plasma glucose"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Unit of measure"/>
    </code>
    <valueCodeableConcept>
      <text value="mg/dL"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Method"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis.   Plasma Fasting Glucose Laboratory Procedure Manual (August 2020)   https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf"/>
    </valueCodeableConcept>
    <exclude value="false"/>
  </characteristic>
</Group>